Abstract
Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia. These children are also known to have a higher risk of relapse and treatment related toxicity. This thesis focused on treatment outcomes and prognostic factors of children with Down syndrome and acute lymphoblastic leukemia. Additionally, this thesis investigated the frequency of targetable lesions in children with Down syndrome acute lymphoblastic leukemia. Finally, this thesis includes the results of a phase 2 clinical trial with inotuzumab ozogamicin monotherapy for children with acute lymphoblastic leukemia but without Down syndrome, which will hopefully attribute to the eligibility of these treatments for children with Down syndrome as well.
Original language | English |
---|---|
Awarding Institution |
|
Supervisors/Advisors |
|
Award date | 2 Oct 2024 |
Place of Publication | Rotterdam |
Print ISBNs | 978-94-6510-105-7 |
Publication status | Published - 2 Oct 2024 |